ReNeuron Group plc

("ReNeuron" or the "Company")

Notice of Results

Investor Presentation

ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, will announce its preliminary results for the year ended 31 March 2021 on Thursday 8 July 2021.

Investor Briefing

Olav Hellebø, Chief Executive Officer, Rick Beckman, Chief Medical Officer and John Hawkins, Financial Controller, will be hosting a live online presentation relating to the preliminary results via the Investor Meet Company platform at 4.30pm on Thursday 8 July. The presentation is open to all existing and potential shareholders.

Investors can sign up to Investor Meet Company for free and register for the presentation here: https://www.investormeetcompany/com/reneuron-group-plc/register-investor

Investors who already follow ReNeuron on the Investor Meet Company platform will automatically be invited.

Questions can be submitted pre-event via your IMC dashboard or in real time during the presentation, via the "Ask a Question" function. Whilst the Company may not be in a position to answer every question it receives, it will address the most prominent within the confines of information already disclosed to the market through regulatory notifications. A recording of the presentation, a PDF of the slides used, and responses to the Q&A session will be available on the Investor Meet Company platform afterwards.

Contacts:

ReNeuron	www.reneuron.com/investors
Olav Hellebø, Chief Executive Officer	Via Walbrook PR

Stifel Nicolaus Europe Limited (NOMAD and Joint Broker) Ben Maddison, Stewart Wallace	+44 (0)20 7710 7600

Allenby Capital Limited (Joint Broker)	+44 (0)20 3328 5656
James Reeve/George Payne (Corporate Finance)
Tim Sohal (Sales & Corporate Broking)

Walbrook PR (Media & Investor Relations)	+44 (0)20 7933 8780 or reneuron@walbrookpr.com
Paul McManus, Alice Woodings	+44 (0)7980 541 893 / +44 (0)7407 804 654

About ReNeuron

ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments for disease with significant unmet needs. The Company's lead cell therapy candidate is in clinical development for the blindness-causing disease, retinitis pigmentosa.

ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that treat diseases of the central nervous system and other disorders. The Company also has the ability through its conditionally immortalised induced pluripotent stem cell (iPSC) platform to make allogeneic tissue cells of choice; in-house programmes are currently focused on treatments for blood cancers and diabetes.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NORBUGDRIDGDGBB